Metropolis Healthcare (NSE:METROPOLIS) Beneish M-Score: -2.55 (As of Jul. 13, 2026)


NSE:METROPOLIS Metropolis Healthcare Ltd NSE:METROPOLIS
95 GF Score
Price ₹567.95
GF Value ₹588.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Metropolis Healthcare Beneish M-Score?

Metropolis Healthcare NSE:METROPOLIS +1.41% 95 Beneish M-Score is -2.55 as of Jul. 13, 2026. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Metropolis Healthcare ranks worse than 54.87% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.55 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Metropolis Healthcare's Beneish M-Score or its related term are showing as below:

NSE:METROPOLIS' s Beneish M-Score Range Over the Past 10 Years
Min: -3.21   Med: -2.58   Max: -1.73
Current: -2.55

During the past 11 years, the highest Beneish M-Score of Metropolis Healthcare was -1.73. The lowest was -3.21. And the median was -2.58.


Metropolis Healthcare Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Metropolis Healthcare's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metropolis Healthcare Beneish M-Score Chart

Metropolis Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.73 -2.84 -2.85 -2.58 -2.55

Metropolis Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 0.00 0.00 0.00 -2.55

NSE:METROPOLIS vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Metropolis Healthcare's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metropolis Healthcare Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Metropolis Healthcare's Beneish M-Score falls into.


NSE:METROPOLIS
95GF Score
Metropolis Healthcare Ltd NSE:METROPOLIS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metropolis Healthcare Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Metropolis Healthcare for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9228+0.528 * 1.0021+0.404 * 0.9483+0.892 * 1.2364+0.115 * 0.9399
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.075152-0.327 * 1.015
=-2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹1,703 Mil.
Revenue was ₹16,458 Mil.
Gross Profit was ₹12,983 Mil.
Total Current Assets was ₹4,686 Mil.
Total Assets was ₹21,381 Mil.
Property, Plant and Equipment(Net PPE) was ₹4,100 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,337 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹3,340 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,383 Mil.
Net Income was ₹1,900 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹3,507 Mil.
Total Receivables was ₹1,493 Mil.
Revenue was ₹13,312 Mil.
Gross Profit was ₹10,523 Mil.
Total Current Assets was ₹3,459 Mil.
Total Assets was ₹18,673 Mil.
Property, Plant and Equipment(Net PPE) was ₹3,615 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,087 Mil.
Selling, General, & Admin. Expense(SGA) was ₹1,862 Mil.
Total Current Liabilities was ₹2,943 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,121 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1702.853 / 16458.459) / (1492.543 / 13312.028)
=0.103464 / 0.11212
=0.9228

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10523.179 / 13312.028) / (12983.244 / 16458.459)
=0.790502 / 0.788849
=1.0021

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4686.121 + 4100.14) / 21380.546) / (1 - (3459.404 + 3614.708) / 18673.402)
=0.589053 / 0.621166
=0.9483

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=16458.459 / 13312.028
=1.2364

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1086.811 / (1086.811 + 3614.708)) / (1337.215 / (1337.215 + 4100.14))
=0.231162 / 0.245931
=0.9399

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 16458.459) / (1861.746 / 13312.028)
=0 / 0.139854
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1382.655 + 3340.221) / 21380.546) / ((1120.579 + 2943.342) / 18673.402)
=0.220896 / 0.217632
=1.015

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1900.174 - 0 - 3506.955) / 21380.546
=-0.075152

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Metropolis Healthcare has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.55 mean?
Metropolis Healthcare (NSE:METROPOLIS) has a Beneish M-Score of -2.55 as of Jul. 13, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Metropolis Healthcare and its competitors. According to the industry distribution chart, Metropolis Healthcare ranks #107 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 54.9%.
Is Metropolis Healthcare's Beneish M-Score too high?
Metropolis Healthcare's current Beneish M-Score is -2.55. Based on the distribution chart, Metropolis Healthcare ranks #107 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #107 out of 195 companies for Beneish M-Score. This places Metropolis Healthcare in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current Beneish M-Score is -2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current Beneish M-Score is -2.55. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Beneish M-Score is -2.55 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?

Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued. The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25. GuruFocus considers Metropolis Healthcare to be Fairly Valued.

Key valuation signals for NSE:METROPOLIS:

  • Beneish M-Score: -2.55
  • GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Metropolis Healthcare Business Description

Other Exchanges 542650:India
Address Dr. Annie Besant Road, 4th Floor, East Wing, Plot-254 B, Nirlon House, Worli, Mumbai, MH, IND, 400 030
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score

Get the complete analysis for NSE:METROPOLIS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹567.95
Price
₹588.25
GF Value